As the NHS grapples with unprecedented demand, workforce pressures and growing elective backlogs, agentic automation is emerging as the key practical lever of choice.
Claus Møldrup, DrugsDisclosed.com Founder and Former Professor in Social Pharmacy at the University of Copenhagen, turns the spotlight on diabetes and explores how to improve patient wellbeing and national health outcomes.
Michelle Vickers, CEO of the Head and Neck Cancer Foundation tells us what we need to know about head and neck cancer treatment, including comment on driving surgical-technological development.
Dr Ganesan Baranidharan, consultant in anaesthesia and pain medicine at the Leeds Teaching Hospitals NHS Trust, explains the power of neuromodulation for managing chronic pain and explains why comprehensive evidence is needed.
Helen Dempster, Founder of Karantis360, explores the benefits of Spark DPS and what future developments are required to improve the public sector health procurement journey even further.
Asymptomatic older patients of COVID-19 are one of the most difficult to identify - now, researchers find that delirium could be an indicator of the virus
Leading pancreatic cancer experts Professor Matthias Löhr and Professor Monique van Leerdam of United European Gastroenterology’s (UEG) Public Affairs Committee discuss the importance of early diagnosis and the latest developments in treatment for pancreatic cancer.
Gino Martini, RPS Chief Scientist and the Science and Research Team at the Royal Pharmaceutical Society reflect on the role of pharmacy during COVID-19 in delivering accessible, safe and effective care for all.
Muy-Teck Teh, Senior Lecturer from Barts and the London School of Medicine & Dentistry, Queen Mary University of London discusses how a novel low-cost rapid digital diagnostic test could help save lives and reduce head and neck cancer burden worldwide.
Elena Posth & Romina Männl from Pfalzklinikum walk us through exactly how the company has entered into a new and exciting era of treating people with mental illness by charting their ‘Innovative psychiatry for the 21st century – Close to domicile. Competent. Human’ project.
A new study, led by researchers at Queen Mary University of London, uses novel biomarkers to predict patient responsiveness to rheumatoid arthritis treatment.
